H4CBD ban in France: a narcotic since 3 June 2024

France's list of narcotics is kept by the Agence nationale de sécurité du médicament (ANSM). On 22 May 2024 the agency added new cannabinoids to that list, and the ban took effect on 3 June 2024. The decision of 22 May 2024 names two CBD derivatives, H2CBD (dihydrocannabidiol) and H4CBD (tetrahydrocannabidiol), as well as eight synthetic cannabinoids. Published on 24 May, it came into force ten days later under its article 3, hence the date of 3 June.

Its scope is wider still, since it also covers "any substance derived from the benzo[c]chromene nucleus". THC is built on that same chemical core, so the wording catches HHC, HHCO, HHCP, HHCPO and THCP in one go, with no need to name each of them. Cannabinol (CBN) is excluded from the outset.

An amending decision of 3 June 2024, published on 4 June, also keeps CBNA, THCV and THCVA up to 0.3% off the list, along with THCA from hemp that complies with the order of 30 December 2021. THCA in a compliant flower is therefore not banned, as our article on THCA explains.

H4CBD is a semi-synthetic cannabinoid: CBD is reacted with hydrogen, in the presence of a catalyst, to saturate the two double bonds it carries outside its aromatic ring, which gives the four hydrogen atoms of the "H4". The Conseil d'État noted that it has not been shown to occur in hemp at detectable concentrations.

H2CBD, or dihydrocannabidiol, gains only two hydrogen atoms: its 8,9-dihydro form has the same molecular formula as HHC, C21H32O2, but the structure of CBD. Hydrogenation also yields two diastereomers, described in 2023 by Collins et al., who call the molecule hexahydrocannabidiol.

This chemistry is not new: in 2006, an Israeli team hydrogenated CBD and obtained several forms of these derivatives, which bound well to the CB1 receptor, the one through which THC produces its effects. On the market, H4-CBD was reported for the first time in 2023, by three European countries, according to the United Nations Office on Drugs and Crime (UNODC).

Do not confuse tetrahydrocannabidiol (H4CBD) with tetrahydrocannabinol (THC): they are two different molecules, both of them controlled. Our article on the three families of cannabinoids separates those of the plant from those that are manufactured.

Nothing supports presenting it as a CBD with no psychoactive effect. The Conseil d'État relied on a survey by the Caen addiction monitoring centre, run from May 2022 (report of 15 November 2023), in which H4-CBD and H2-CBD show a "cannabinergic psychoactive profile". For the semi-synthetic cannabinoids studied as a whole, the effects reported are most often comparable to those of THC at equivalent doses, with risks heightened by the high concentration of the products.

The 2006 study measured binding to the receptor, in vitro, on rat brain tissue, which says nothing about an effect in humans. In 2025 a team in Bern even judged that affinity weak and the psychoactivity of H4CBD unclear, since user reports were divided (Schirmer et al.). We found no controlled trial in humans, and no primary source for the "100 times stronger than CBD" claim sometimes seen.

A product sold as CBD that gets you high most often contains something else: see our article on a CBD that gets you high.

CBD comes from the plant and remains allowed under conditions; H4CBD and HHC, most often made from CBD, are both narcotics.

The HHC timeline is traced in our article on HHC.

Yes. On 6 June 2025, the Conseil d'État dismissed the appeals brought by the Union des professionnels du CBD and several companies against the ANSM decisions of 22 May and 3 June 2024 (decision no. 494779, joined with applications no. 494973 and 495486).

For the court, in the current state of scientific knowledge these substances are narcotics, so they fall outside the free movement of goods under article 34 of the Treaty on the Functioning of the European Union. As their natural presence in hemp has not been established, the classification does not in effect ban hemp farming. The court found no manifest error of assessment and upheld the exclusions of THCA and THCV.

Our article on the CJEU's Kanavape judgment explains why CBD, by contrast, moves between member states. The arguments of a ban "awaiting a court ruling" or of a "legal vacuum" therefore no longer hold.

No ban applies worldwide: H4CBD is not listed in any international convention. France placed it in annex IV of its list, which is reserved for substances classified in France or in the European Union but not by the conventions. It was not among the substances on the agenda of the 49th meeting of the WHO Expert Committee, scheduled for 19 to 22 October 2026.

Spain classified it through Orden SND/380/2025, in force since 23 April 2025: "hidrocannabidiol (H4-CBD; tetrahidrocannabidiol)" joins list II of psychotropic substances. See our article on CBD in Spain.

For other countries, we have read no official text; the Bern team cited above noted in 2025 that only a few countries had classified it. A product sold freely abroad is still a narcotic in France, and the law of the country you are in applies, stopovers included: see our article on travelling with CBD.

The ANSM bases its decisions on reports from France's addiction monitoring centres. For these new cannabinoids, it lists serious effects: vomiting, loss of consciousness, coma, seizures, paranoia, anxiety, high blood pressure, a racing heart, chest pain and kidney failure. Its decision cites psychoactive effects similar to those of delta-9-THC and a risk of dependence, which justified classifying them without delay, as a precaution.

A study run with Lille University Hospital pointed the same way: of 223 "CBD" products bought in 2022 and 2023, 12 contained an undeclared semi-synthetic cannabinoid, which is 5.4%, among them H4-CBD and HHC.

The ban did not empty the market. On 19 June 2025, the ANSM and Anses warned of several hundred poisonings linked since early 2024 to products sold as CBD, most often caused by THC above the threshold or by cannabinoids such as HHC, HHC-O or H4-CBD. They advise particular caution with products labelled "potent".

In 2025, the SINTES system of the OFDT, the French drug observatory, still identified H4-CBD six times, against twice for HHC (Point SINTES no. 11, June 2026). In the 2024 and 2025 collections where synthetic or semi-synthetic cannabinoids were identified, the sweets held only semi-synthetics (HHC, delta-8-THC or H4-CBD), and H4-CBD was also identified in an e-liquid. The same review notes many adulterations, most often without users knowing, in products sold over the counter: CBD shops, tobacconists, vending machines. See also our articles on synthetic cannabinoids in CBD and on delta-8-THC.

French narcotics law has applied to H4CBD since 3 June 2024, with no tolerance threshold. The 0.30% limit concerns only Δ⁹-THC in hemp and makes no quantity of H4CBD legal. That threshold is explained in our article on the legal THC level.

Since law no. 2020-1525 of 7 December 2020 and decree no. 2022-113 of 1 February 2022, it is the director general of the ANSM who amends the list, through decisions published on the agency's website. The version of the order of 22 February 1990 on Légifrance does not include them. To check a molecule, consult the ANSM consolidated list, updated on 26 June 2026: it is for information only, and only the order and the decisions are binding.

Since 20 August 2026, the fixed fine for drug use has been €500, reduced to €400 if paid within 15 days and increased to €1,000 after 45 days. A retailer has no room for argument: one H4CBD product on the shelf counts as possessing and offering a narcotic.

Status checked on 28 October 2026: CBG and CBN remain off the list, THCA from compliant hemp is excluded, and H2CBD and THCP have been classified since 3 June 2024.

Start with the label. In France, a product listing "H4CBD", "H4-CBD", "tetrahydrocannabidiol", "hexahydrocannabidiol", "hydrogenated CBD" or "CBD hydrogéné" is illegal. Also distrust any product sold as "stronger than CBD" or with a "THC-like effect". Compliant CBD does not get you high, so such a promise often signals an additive.

Then read the lab report. The Lille study shows that liquid chromatography coupled with mass spectrometry lets a laboratory test for H4-CBD, HHC or Δ⁸-THC, provided it actually looks for them. On a certificate, make sure these molecules are in the list of compounds tested, with a "not detected" result and a detection limit. If a certificate lists only CBD and THC, it tells you nothing about derivatives.

Each line is explained in our guide to reading a certificate of analysis, and the laboratory page describes the measurement methods.

Stop using it. Call 15 or 112 if someone loses consciousness or suddenly feels very unwell; for other symptoms, see a doctor or call a poison control centre, open day and night on 01 45 42 59 59. Deaf or hard-of-hearing people can reach 114 by text message, app or internet.

Tell the medical staff what you took: according to the ANSM, these cannabinoids are not picked up by standard urine screening and require a specialised analysis. Keep what is left of the product for the SINTES system and report the adverse effect on signalement.social-sante.gouv.fr. In young children, accidental ingestion can be serious: see what to do if a child swallows a product.

To cut down or stop, a doctor or an addiction service can support you; under 25, a youth consultation service (consultation jeunes consommateurs) sees you free of charge and in confidence. Drogues Info Service answers free of charge and anonymously on 0 800 23 13 13.